This HTML5 document contains 60 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n22http://linked.opendata.cz/resource/drugbank/drug/DB00347/identifier/wikipedia/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00347/identifier/pharmgkb/
foafhttp://xmlns.com/foaf/0.1/
n15http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n17http://linked.opendata.cz/resource/drugbank/dosage/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00347/identifier/bindingdb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00347/identifier/pubchem-compound/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00347/identifier/pubchem-substance/
n21http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB00347/identifier/kegg-drug/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00347/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n10http://www.drugs.com/mtm/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00347/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/atc/
n23http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00347
rdf:type
n3:Drug
n3:description
An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)
n3:dosage
n17:271B5CD3-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
Used in the control of absence (petit mal) seizures that are refractory to treatment with other medications.
n3:manufacturer
n5:271B5CD2-363D-11E5-9242-09173F13E4C5
owl:sameAs
n19:DB00347 n21:DB00347
dcterms:title
Trimethadione
adms:identifier
n7:5374 n8:DB00347 n11:50019167 n12:5576 n13:46504478 n16:D00392 n20:PA164744924 n22:Trimethadione
n3:mechanismOfAction
Dione anticonvulsants reduce T-type calcium currents in thalamic neurons, including thalamic relay neurons. It does so via the inhibition of voltage dependent T-type calcium channels. This raises the threshold for repetitive activity in the thalamus, and inhibits corticothalamic transmission. Thus, the abnormal thalamocortical rhythmicity, which is thought to underlie the 3-Hz spike-and-wave discharge seen on electroencephalogram(EEG) with absence seizures, is dampened.
n3:packager
n5:271B5CD1-363D-11E5-9242-09173F13E4C5
n3:synonym
Trimethadionum Trimethinum Trimethadion Tridione Troxidone Triméthadione
n3:toxicity
Symptoms of overdose include clumsiness or unsteadiness, coma, dizziness (severe), drowsiness (severe), nausea (severe), and problems with vision.
n3:proteinBinding
90%
n14:hasConcept
n15:M0021989
foaf:page
n10:trimethadione.html
n3:IUPAC-Name
n4:271B5CD8-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5CDE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5CDD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5CDA-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5CDB-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5CDC-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5CD6-363D-11E5-9242-09173F13E4C5 n4:271B5CEC-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5CD4-363D-11E5-9242-09173F13E4C5 n4:271B5CEE-363D-11E5-9242-09173F13E4C5 n4:271B5CD7-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5CD5-363D-11E5-9242-09173F13E4C5
n23:hasATCCode
n24:N03AC02
n3:H-Bond-Acceptor-Count
n4:271B5CE4-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5CE5-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5CDF-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5CE0-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5CE2-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5CE1-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5CE3-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
127-48-0
n3:category
n3:Bioavailability
n4:271B5CE8-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5CEA-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5CEB-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5CED-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5CE7-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5CE6-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5CE9-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5CD9-363D-11E5-9242-09173F13E4C5